At a glance
ClinicalIndex Comparison RecordN/ACompleted· 624 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Determining Prevalence of Acute Bilirubin Encephalopathy in Developing Countries
In Brief
An observational study for Hyperbilirubinemic Encephalopathy. Completed, enrolled 624 participants across 1 site.
Detailed Summary
The investigators hypothesize that a new BIND (Bilirubin Induced Neurologic Dysfunction) scoring method adapted for the developing world (BIND II, developed by our team for use by health care workers), with additional modifications for community use (the community BIND, C-BIND), will improve the ability to identify infants with ABE and to distinguish ABE from other common causes of neonatal morbidity and mortality compared to currently available survey tools.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHyperbilirubinemic Encephalopathy
CountriesNigeria
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2012
First PostedDec 2012
Primary CompletionFeb 2015
TodayJul 2026
First PostedDec 21, 2012
Enrollment StartDec 1, 2012
Primary CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 13.5 years ago